Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SRY-box transcription factor 2 (SOX2) promoter contains a nuclease hypersensitive element (NHE) with a G-rich sequence homologous to the c-MYC Pu27 region, which is capable of folding into G-quadruplex (G4) structures (Source: Scientific Reports 2017;7:10138). The complementary C-rich strand of this region can also form i-motif structures, which serve as additional regulatory switches for gene expression (Source: Bioorg Med Chem Lett 2018;28:1518). These non-canonical DNA structures play a critical role in regulating the transcription of SOX2, a master transcription factor essential for maintaining the pluripotency and self-renewal of embryonic and cancer stem cells (Source: UniProt P48431). SOX2 is frequently overexpressed in aggressive malignancies, including glioblastoma and lung cancer, where it drives tumor progression and resistance to therapy (Source: PubMed 28844886). Small molecule ligands that stabilize these G4 or i-motif structures can effectively downregulate SOX2 expression, offering a therapeutic strategy to target cancer stemness and overcome chemoresistance (Source: Nucleic Acids Res 2014;42:7422). However, achieving high selectivity for the SOX2-specific sequence over other genomic G-quadruplexes remains a significant challenge in drug development (Source: PubMed 30245445).
Stabilization of G-quadruplex or i-motif structures within the SOX2 promoter to sterically hinder transcription factor binding and RNA polymerase recruitment, leading to transcriptional repression of the SOX2 gene.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRY-box transcription factor 2 (SOX2) promoter G-quadruplex and i-motif region (SOX2 promoter G4/i-motif).